All In Biotech

Drug Trial Radar · NCT00741585

Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

Last checked: Nov 19, 2026Latest source record: Aug 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 21,983 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

21,983

Actual

Start

Sep 1, 2008

Primary completion

Jun 30, 2018

Study completion Jun 30, 2018

Sponsor

Lead sponsor
University of VigoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Servicio Gallego de Salud
First posted
Aug 26, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The HYGIA study was designed to investigate prospectively 1. the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings 2. the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients 3. the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients 4. the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.

Conditions

  • Essential Hypertension
  • Cardiovascular Disease
  • Stroke
  • Chronic Kidney Disease

Interventions

  • Any antihypertensive medication alone or in combinationDrug

    All drugs on awakening

  • Any antihypertensive medication alone or in combinationDrug

    One or more drugs at bedtime

  • Ambulatory blood pressure monitoringDevice

    Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.Time frame: Yearly evaluation for at least ten years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • CS Fingoi

    Lugo, Spain

  • Complexo Hospitalario Universitario de Ourense

    Ourense, Spain

  • CS Lerez

    Pontevedra, Spain

  • CS Friol

    Friol, Lugo, Spain

  • CS A Estrada

    A Estrada, Pontevedra, Spain

  • CS Baiona

    Baiona, Pontevedra, Spain

  • CS Bueu

    Bueu, Pontevedra, Spain

  • CS A Guarda

    La Guardia, Pontevedra, Spain

  • CS Valmiñor

    Nigrán, Pontevedra, Spain

  • CS Panxón

    Nigrán, Pontevedra, Spain

  • CS Tomiño

    Tomiño, Pontevedra, Spain

  • Bioengineering & Chronobilogy Labs., University of Vigo

    Vigo, Pontevedra, Spain

  • Hospital do Meixoeiro

    Vigo, Pontevedra, Spain

  • CS Calle Cuba

    Vigo, Pontevedra, Spain

  • CS A Doblada

    Vigo, Pontevedra, Spain

  • CS Coia

    Vigo, Pontevedra, Spain

  • CS Sardoma

    Vigo, Pontevedra, Spain

  • CS Teis

    Vigo, Pontevedra, Spain

  • CS Vilaboa

    Vilaboa, Pontevedra, Spain

  • CS San Roque

    Vilagarcía de Arousa, Pontevedra, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.